NMS is an acute onset due to D2 receptor antagonism and is more common with which type of antipsychotics?

NMS is an acute onset due to D2 receptor antagonism and is more common with which type of antipsychotics?

• A. Low-potency FGAs
• B. High-potency FGAs
• C. SGAs
• D. Anticholinergics

Answer: (B)

Neuroleptic malignant syndrome happens when strong dopamine D2 receptor blockade occurs in the brain, especially in the nigrostriatal pathway. The most potent and rapid D2 blockade comes from high-potency first-generation antipsychotics (like haloperidol and related drugs), so this class carries the highest risk of NMS. Their intense D2 antagonism drives the acute motor symptoms and autonomic instability that define NMS, often appearing soon after starting therapy or after a dose increase. In contrast, low-potency first-generation antipsychotics block D2 less aggressively and have more pronounced anticholinergic and antihistaminic effects, which somewhat mitigate the risk of NMS. Atypical antipsychotics (SGAs) also tend to lower NMS risk due to their more balanced receptor profiles and less consistent strong D2 blockade in motor pathways. Anticholinergic drugs aren’t a cause of NMS; they’re not antipsychotics and don’t produce this syndrome, though they can influence the clinical picture.

Neuroleptic malignant syndrome happens when strong dopamine D2 receptor blockade occurs in the brain, especially in the nigrostriatal pathway. The most potent and rapid D2 blockade comes from high-potency first-generation antipsychotics (like haloperidol and related drugs), so this class carries the highest risk of NMS. Their intense D2 antagonism drives the acute motor symptoms and autonomic instability that define NMS, often appearing soon after starting therapy or after a dose increase.

In contrast, low-potency first-generation antipsychotics block D2 less aggressively and have more pronounced anticholinergic and antihistaminic effects, which somewhat mitigate the risk of NMS. Atypical antipsychotics (SGAs) also tend to lower NMS risk due to their more balanced receptor profiles and less consistent strong D2 blockade in motor pathways. Anticholinergic drugs aren’t a cause of NMS; they’re not antipsychotics and don’t produce this syndrome, though they can influence the clinical picture.